Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Intern Med ; 54: 76-80, 2018 08.
Article in English | MEDLINE | ID: mdl-29934240

ABSTRACT

BACKGROUND: Thalassemia minor (Tm) individuals, are generally considered healthy. However, the prognosis of Tm individuals has not been extensively studied. The aim of this study was to evaluate the prognosis of Tm versus controls without ß-thalassemia carrier state. METHODS: A total of 26,006 individuals seeking thalassemia screening at the AOOR Villa Sofia-V. Cervello, Palermo (Italy) were retrospectively studied. Logistic penalised regression model was used to estimate risk of potential complications and survival techniques were used to study mortality. RESULTS: We identified a total of 4943 Tm and 21,063 controls. Tm was associated with significantly higher risks of hospitalisation for cirrhosis (OR 1·94, 95% CI 1·30 to 2·90, p = 0·001), kidney disorders (OR 2·11, 95% CI 1·27 to 3·51, p = 0·004), cholelithiatis (OR 1·39, 95% CI 1·08 to 1·79, p = 0·010), and mood disorders (OR 2·08, 95% CI 1·15 to 3·75, p = 0·015). No statistically difference in life expectancy between thalassemia minor and control group was found (HR 1·090, 95% CI 0·777 to 1·555, p < 0·590; log-rank test p = .426). CONCLUSION: This study shows that Tm affects the prognosis of Tm carriers regarding health expectation. Probably, iron overload and anaemia for several years may be at the basis of these effects.


Subject(s)
Heterozygote , Life Expectancy , beta-Thalassemia/genetics , beta-Thalassemia/mortality , Cholelithiasis/complications , Hospitalization , Humans , Italy , Kidney Diseases/complications , Liver Cirrhosis/complications , Logistic Models , Mood Disorders/complications
2.
Hemoglobin ; 42(1): 68-71, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29633668

ABSTRACT

We studied the clinical, electrocardiographic, echocardiographic, Doppler and T2* cardiac magnetic resonance (CMR) data of all adult ß-thalassemia major (ß-TM) patients with heart failure (HF) consecutively observed at our referral center of the Sicilian region between 2008 and 2016. There were 16 patients enrolled in the study. Echocardiographic examination showed that only one patient had HF with systolic dysfunction of the left ventricle (HFrEF), whereas the others had HF with preserved systolic function of the left ventricle (HFpEF). Systolic dysfunction of the right ventricle (RV) was observed in 13 cases. Furthermore, 30.0% of the patients presented T2* CMR values consistent with intermediate risk of systolic dysfunction of the left ventricle (LV) due to iron overload, whereas 70.0% had normal values. Typical electrocardiographic abnormalities (wide T wave inversion and low voltages) were observed in 11 out of 16 patients. In conclusion, in the adult ß-TM patients with HF recently observed at our center, the predominant form was that with diastolic dysfunction of the LV, and with systolic dysfunction of the RV. Only 30.0% had low values of T2* CMR. Typical electrocardiographic abnormalities were found in 69.0%.


Subject(s)
Heart Failure/physiopathology , beta-Thalassemia/complications , Adult , Electrocardiography , Female , Heart Failure/etiology , Humans , Male , Middle Aged , Ventricular Dysfunction, Left/physiopathology , Ventricular Dysfunction, Right/physiopathology , beta-Thalassemia/physiopathology
3.
Eur J Haematol ; 100(2): 124-130, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29094403

ABSTRACT

OBJECTIVES: The liver remains the primary site of iron storage, with liver iron concentration (LIC) being a strong surrogate of total body iron. MRI-R2 can accurately measure LIC. The LICNET (Liver Iron Cutino Network) was established to diagnostics of liver iron overload by MRI-R2 subjects with hemochromatosis in hematological disorders. The aims of the study were to look at variation in LIC measurements during time across different chelation regimens. METHODS: This was a cross-sectional study of 130 patients attending 9 Italian centers participating in the LICNET. LIC comparisons over time (T0 and T1 ) were made using t test and/or Wilcoxon test. RESULTS: LIC significantly decreased from MRI1 to MRI2 although at high variance (median change -0.8 mg Fe/g dw, range: -29.0 to 33.0; P = .011) and 7.7% of patients shifted from LIC values of high risk (>15 mg Fe/g dw) to an intermediate-risk category (7-15 mg Fe/g dw). Median change in LIC and correlation with serum ferritin levels (SF), during different chelation regimens, is reported. CONCLUSIONS: These findings suggest as longitudinal variation in the LIC is possible, across all chelation regimens. It confirms as SF levels not always can be used for estimating changes in LIC.


Subject(s)
Iron Overload/metabolism , Iron Overload/pathology , Iron/metabolism , Liver/metabolism , Liver/pathology , Adolescent , Adult , Aged , Biomarkers/blood , Chelation Therapy , Child , Cross-Sectional Studies , Female , Ferritins/blood , Humans , Iron Chelating Agents/therapeutic use , Iron Overload/diagnostic imaging , Iron Overload/etiology , Liver/diagnostic imaging , Liver/drug effects , Magnetic Resonance Imaging/methods , Male , Middle Aged , Young Adult
4.
Eur J Haematol ; 97(4): 361-70, 2016 Oct.
Article in English | MEDLINE | ID: mdl-26818147

ABSTRACT

BACKGROUND: Real-life data on the use of R2 MRI for the assessment of liver iron concentration (LIC) remain limited. METHODS: We conducted a cross-sectional analysis on 363 patients (mean age 35.6 yr, 44.1% men) with hemoglobinopathies (204 ß-thalassemia major [TM], 102 ß-thalassemia intermedia [TI], and 57 sickle cell disease [SCD]) that were evaluated with R2 MRI as part of LICNET, an MRI network of 13 Italian treatment centers. RESULTS: The mean LIC was 7.8 mg/g (median: 4.0), with high LIC (>7 mg/g) noted in both transfused (TM, TI 37%; SCD 38%) and non-transfused (TI 20%) patients. Ferritin levels correlated with LIC in both transfused (TM, TI, SCD) and non-transfused (TI) patients (P < 0.001), although lower values predicted high LIC in non-transfused patients (1900 vs. 650 ng/mL in TM vs. non-transfused TI). A correlation between LIC and ALT levels was only noted in HCV-negative patients (rs = 0.316, P < 0.001). The proportion of patients with high LIC was significantly different between iron chelators used (P = 0.023), with the lowest proportion in deferasirox (30%) and highest in deferiprone (53%)-treated patients. CONCLUSIONS: High LIC values persist in subgroups of patients with hemoglobinopathy, warranting closer monitoring and management optimization, even for non-transfused patients with relatively low ferritin levels.


Subject(s)
Hemoglobinopathies/complications , Iron Overload/diagnosis , Iron Overload/etiology , Iron/metabolism , Liver/metabolism , Liver/pathology , Magnetic Resonance Imaging , Adolescent , Adult , Aged , Alanine Transaminase/blood , Biomarkers , Child , Comorbidity , Cross-Sectional Studies , Female , Ferritins/blood , Hemoglobinopathies/diagnosis , Humans , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Magnetic Resonance Imaging/methods , Male , Middle Aged , Young Adult
5.
Hematol Rep ; 8(4): 6678, 2016 Nov 02.
Article in English | MEDLINE | ID: mdl-28053695

ABSTRACT

Increased expression of fetal hemoglobin (HbF) may ameliorate the clinical course of hemoglobinopathies. Hydroxyurea (HU) is the only inducer approved for the treatment of these diseases able to stimulate HbF production but patients' response is highly variable indicating the utility of the identification of pharmacogenomic biomarkers in order to predict pharmacological treatment efficacy. To date few studies to evaluate the role of genetic determinants in HU response have been conducted showing contradictory results. In this study we analyzed BCL11A, GATA-1, KLF-1 genes and γ-globin promoter in 60 alleles from 30 hemoglobinopathies patients under HU treatment to assess the role of these markers in HU response. We did not find any association between these genetic determinants and HU response. Before treatment started, the same patients were analyzed in vitro using liquid erythroid cultures in a test able to predict their response to HU. The results of our analysis confirm the absence of pharmacogenomic biomarker associated to HU response indicating that, the quantification of γ-globin mRNA fold increase remains the only method able to predict in vivo patients response to the drug.

6.
Hemoglobin ; 39(4): 225-9, 2015.
Article in English | MEDLINE | ID: mdl-26016899

ABSTRACT

Phenotypic improvement of hemoglobinopathies such as sickle cell disease and ß-thalassemia (ß-thal) has been shown in patients with high levels of Hb F. Among the drugs proposed to increase Hb F production, hydroxyurea (HU) is currently the only one proven to improve the clinical course of these diseases. However, Hb F increase and patient's response are highly variable, indicating that new pharmacological agents could be useful for patients not responding to HU or showing a reduction of response during long-term therapy. In this study we evaluated the efficacy of rapamycin, a lypophilic macrolide used for the prevention of acute rejection in renal transplant recipients, as an inducer of Hb F production. The analyses were performed in cultured erythroid progenitors from 25 sickle cell disease and 25 ß-thal intermedia (ß-TI) patients. The use of a quantitative Real-Time-polymerase chain reaction ReTi-PCR technique and high performance liquid chromatography (HPLC) allowed us to determine the increase in γ-globin mRNA expression and Hb F production in human erythroid cells treated with rapamycin. The results of our study demonstrated an increase in vitro of γ-globin mRNA expression in 15 sickle cell disease and 14 ß-TI patients and a corresponding Hb F increase. The induction by rapamycin, even if lower or similar in most of samples analyzed, in some cases was higher than HU. These data suggest that rapamycin could be a good candidate to be used in vivo for the treatment of hemoglobinopathies.


Subject(s)
Anemia, Sickle Cell/genetics , Erythroid Precursor Cells/drug effects , Erythroid Precursor Cells/metabolism , Fetal Hemoglobin/genetics , Gene Expression Regulation/drug effects , Sirolimus/pharmacology , beta-Thalassemia/genetics , Adolescent , Adult , Aged , Anemia, Sickle Cell/drug therapy , Anemia, Sickle Cell/metabolism , Cells, Cultured , Female , Fetal Hemoglobin/metabolism , Genotype , Humans , Hydroxyurea/pharmacology , Hydroxyurea/therapeutic use , Male , Middle Aged , Mutation , Young Adult , alpha-Globins/genetics , alpha-Globins/metabolism , beta-Globins/genetics , beta-Globins/metabolism , beta-Thalassemia/drug therapy , beta-Thalassemia/metabolism , gamma-Globins/genetics , gamma-Globins/metabolism
7.
Am J Hematol ; 90(7): 634-8, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25809173

ABSTRACT

In patients with thalassemia intermedia (TI), such as beta-TI, alpha-thalassemia (mainly HbH disease and mild/moderate forms of HbE/beta-thalassemia), iron overload is an important challenge in terms of diagnosis, monitoring, and treatment. Moreover, to date, the only possible chelators available are deferoxamine, deferasirox, and deferiprone. Here, we report the first 5-year long-term randomized clinical trial comparing the effectiveness of deferiprone versus deferoxamine in patients with TI. Body iron burden, which was determined by measuring serum ferritin levels in the same patient over 5 years and analyzed according to the generalized linear mixed model (GLMM), showed a linear decrease over time in the mean serum ferritin levels in both treatment groups (P-value = 0.035). The overall period of observation was 235.2 person-years for the deferiprone patients compared with 214.3 person-years for the deferoxamine patients. The results of the log-rank test suggested that the deferiprone treatment did not affect survival compared with the deferoxamine treatment (P-value = 0.360). The major adverse events observed included gastrointestinal symptoms and joint pain or arthralgia. Neutropenia and agranulocytosis were also detected, suggesting needing of strict hematological control. In conclusion, long-term iron chelation therapy with deferiprone is associated with an efficacy and safety similar to that of deferoxamine, suggesting that this drug is an alternative option in cases in which deferoxamine and deferasirox are contraindicated.


Subject(s)
Deferoxamine/administration & dosage , Iron Chelating Agents/administration & dosage , Iron Overload/therapy , Pyridones/administration & dosage , beta-Thalassemia/therapy , Adult , Agranulocytosis/chemically induced , Agranulocytosis/physiopathology , Arthralgia/chemically induced , Arthralgia/physiopathology , Chelation Therapy/methods , Deferiprone , Deferoxamine/adverse effects , Female , Ferritins/metabolism , Humans , Iron Chelating Agents/adverse effects , Iron Overload/etiology , Iron Overload/metabolism , Iron Overload/mortality , Linear Models , Male , Middle Aged , Neutropenia/chemically induced , Neutropenia/physiopathology , Pyridones/adverse effects , Survival Analysis , Transfusion Reaction , beta-Thalassemia/metabolism , beta-Thalassemia/mortality , beta-Thalassemia/pathology
8.
Blood Cells Mol Dis ; 53(4): 265-71, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24814618

ABSTRACT

Blood transfusion and iron chelation currently represent a supportive therapy to manage anemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease. Here we describe the first 5-year long-term randomized clinical trial comparing Deferiprone versus Deferoxamine in patients with Sickle-Cell-Disease. The results of this study show that Deferiprone has the same effectiveness as Deferoxamine in decreasing body iron burden, measured as repeated measurements of serum ferritin concentrations on the same patient over 5-years and analyzed according to the linear mixed-effects model (LMM) (p=0.822). Both chelators are able to decrease, significantly, serum ferritin concentrations, during 5-years, without any effect on safety (p=0.005). Moreover, although the basal serum ferritin levels were higher in transfused compared with non-transfused group (p=0.031), the changes over time in serum ferritin levels were not statistically significantly different between transfused and non-transfused cohort of patients (p=0.389). Kaplan-Meier curve, during 5-years of study, suggests that Deferiprone does not alter survival in comparison with Deferoxamine (p=0.38). In conclusion, long-term iron chelation therapy with Deferiprone was associated with efficacy and safety similar to that of Deferoxamine. Therefore, in patients with Sickle-Cell-Disease, Deferiprone may represent an effective long-term treatment option.


Subject(s)
Anemia, Sickle Cell/drug therapy , Deferoxamine/therapeutic use , Iron Chelating Agents/therapeutic use , Iron Overload/drug therapy , Pyridones/therapeutic use , Adolescent , Adult , Anemia, Sickle Cell/blood , Anemia, Sickle Cell/mortality , Anemia, Sickle Cell/pathology , Blood Transfusion , Child , Deferiprone , Female , Ferritins/blood , Humans , Iron/blood , Iron Overload/blood , Iron Overload/mortality , Iron Overload/pathology , Italy , Linear Models , Male , Middle Aged , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...